About this Journal Submit a Manuscript Table of Contents
Sarcoma
Volume 2013 (2013), Article ID 725305, 19 pages
http://dx.doi.org/10.1155/2013/725305
Research Article

Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden

1Catalyst Health Economics Consultants, 34b High Street, Northwood, Middlesex HA6 1BN, UK
2School of Biomedical Sciences, King’s College, London SE1 1UL, UK
3Palliative Care Department, Royal Marsden Hospital, London SW3 6JJ, UK
4Sarcoma Unit, Royal Marsden Hospital, London SW3 6JJ, UK

Received 13 May 2013; Accepted 20 August 2013

Academic Editor: R. Pollock

Copyright © 2013 Julian F. Guest et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Cassier, S. I. Labidi-Galy, P. Heudel et al., “Therapeutic pipeline for soft-tissue sarcoma,” Expert Opinion on Pharmacotherapy, vol. 12, no. 16, pp. 2479–2491, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. Clark, C. Fisher, I. Judson, and J. M. Thomas, “Soft-tissue sarcomas in adults,” The New England Journal of Medicine, vol. 353, no. 7, pp. 701–711, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Penel, C. Nisse, S. Feddal, and E. Lartigau, “Soft tissue sarcoma,” Presse Medicale, vol. 30, no. 28, pp. 1405–1413, 2001. View at Scopus
  4. “Cancer Research UK,” 2011, http://www.cancerresearchuk.org/home/.
  5. M. F. Brennan, E. S. Casper, and L. B. Harrison, “Soft tissue sarcoma,” in Cancer: Principles and Practice of Oncology, V. T. deVita Jr., S. Hellman, and S. A. Rosenberg, Eds., pp. 1738–1788, Lippincott-Ravel Publishers, Philadelphia, Pa, USA, 5th edition, 1997.
  6. A. Misra, N. Mistry, R. Grimer, and F. Peart, “The management of soft tissue sarcoma,” Journal of Plastic, Reconstructive and Aesthetic Surgery, vol. 62, no. 2, pp. 161–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. F. Abellan, J. M. Lamo de Espinosa, J. Duart et al., “Nonreferral of possible soft tissue sarcomas in adults: a dangerous omission in policy,” Sarcoma, vol. 2009, Article ID 827912, 7 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. J. M. Coindre, P. Terrier, L. Guillou et al., “Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group,” Cancer, vol. 91, no. 10, pp. 1914–1926, 2001. View at Publisher · View at Google Scholar
  9. M. van Glabbeke, A. T. van Oosterom, J. W. Oosterhuis et al., “Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline- containing first-line regimens—a European organization for research and treatment of Cancer Soft Tissue and Bone Sarcoma Group Study,” Journal of Clinical Oncology, vol. 17, no. 1, pp. 150–157, 1999. View at Scopus
  10. A. Italiano, M. Toulmonde, and B. Bui-Nguyen, “Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines,” Bulletin du Cancer, vol. 97, no. 6, pp. 679–686, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Thornton, C. E. Pesce, and M. A. Choti, “Multidisciplinary management of metastatic sarcoma,” Surgical Clinics of North America, vol. 88, no. 3, pp. 661–672, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. The ESMO/European Sarcoma Network Working Group, “Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 23, supplement 7, pp. vii92–vii99, 2012.
  13. S. Verma and V. Bramwell, “Dose-intensive chemotherapy in advanced adult soft tissue sarcoma,” Expert Review of Anticancer Therapy, vol. 2, no. 2, pp. 201–215, 2002. View at Scopus
  14. J. M. Buesa, A. López-Pousa, J. Martín et al., “Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS),” Annals of Oncology, vol. 9, no. 8, pp. 871–876, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Verweij and H. M. Pinedo, “Systemic treatment of advanced or metastatic soft tissue sarcoma,” in Soft Tissue Sarcomas: New Developments in the Multidisciplinary Approach to Treatment, H. M. Pinedo, J. Verweij, and H. D. Suit, Eds., pp. 75–91, Kluwer Academic, Boston, Mass, USA, 1991.
  16. J. Schütte, R. Kellner, and S. Seeber, “Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen,” Cancer Chemotherapy and Pharmacology, vol. 1, no. 2, pp. S194–S198, 1993. View at Scopus
  17. A. Santoro, T. Tursz, H. Mouridsen et al., “Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first- line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group,” Journal of Clinical Oncology, vol. 13, no. 7, pp. 1537–1545, 1995. View at Scopus
  18. R. Garcia-Carbonero, J. G. Supko, R. G. Maki et al., “Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5484–5492, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. A. L. Cesne, J. Y. Blay, I. Judson et al., “Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 576–584, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Fayette, I. R. Coquard, L. Alberti, D. Ranchère, H. Boyle, and J.-Y. Blay, “ET-743: a novel agent with activity in soft tissue sarcomas,” Oncologist, vol. 10, no. 10, pp. 827–832, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. M. M. Oken, R. H. Creech, and T. E. Davis, “Toxicology and response criteria of the Eastern Cooperative Oncology Group,” American Journal of Clinical Oncology, vol. 5, no. 6, pp. 649–655, 1982. View at Scopus
  22. J. L. Mansi, C. Fisher, E. Wiltshaw, S. MacMillan, M. King, and R. Stuart-Harris, “A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma,” European Journal of Cancer and Clinical Oncology, vol. 24, no. 9, pp. 1439–1443, 1988. View at Scopus
  23. F. P. Worden, J. M. G. Taylor, J. S. Biermann et al., “Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma,” Journal of Clinical Oncology, vol. 23, no. 1, pp. 105–112, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Le Cesne, I. Judson, D. Crowther et al., “Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus infosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group,” Journal of Clinical Oncology, vol. 18, no. 14, pp. 2676–2684, 2000. View at Scopus
  25. C. Bokemeyer, A. Franzke, J. T. Hartmann, et al., “A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas,” Cancer, vol. 80, no. 7, pp. 1221–1227, 1997. View at Publisher · View at Google Scholar
  26. T. de Pas, F. de Braud, L. Orlando et al., “High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?” Annals of Oncology, vol. 9, no. 8, pp. 917–919, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Wall and H. Starkhammar, “Chemotherapy of soft tissue sarcoma: a clinical evaluation of treatment over ten years,” Acta Oncologica, vol. 42, no. 1, pp. 55–61, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Leyvraz, M. Bacchi, T. Cerny et al., “Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK),” Annals of Oncology, vol. 9, no. 8, pp. 877–884, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Schütte, H. T. Mouridsen, W. Steward et al., “Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma,” Cancer Chemotherapy and Pharmacology, vol. 31, no. 2, pp. S204–S209, 1993. View at Scopus
  30. A. Comandone, S. Bretti, O. Bertetto, C. Oliva, P. Bergnolo, and C. Bumma, “Low dose adriamycin and ifosfamide in the treatment of advanced adult soft tissue sarcomas,” Anticancer Research B, vol. 20, no. 3, pp. 2077–2080, 2000. View at Scopus
  31. I. Barişta, G. Tekuzman, S. Yalçin, et al., “Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy,” Journal of Surgical Oncology, vol. 73, no. 1, pp. 12–16, 2000.
  32. R. E. Hawkins, E. Wiltshaw, and J. L. Mansi, “Ifosfamide with and without adriamycin in advanced uterine leiomyosarcoma,” Cancer Chemotherapy and Pharmacology, vol. 26, pp. S26–S29, 1990. View at Publisher · View at Google Scholar · View at Scopus
  33. P. J. Loehrer Sr., G. W. Sledge Jr., C. Nicaise et al., “Ifosfamide plus doxorubicin in metastatic adult sarcomas: a multi-institutional phase II trial,” Journal of Clinical Oncology, vol. 7, no. 11, pp. 1655–1659, 1989. View at Scopus
  34. G. D. Demetri, “ET-743: the US experience in sarcomas of soft tissues,” Anti-Cancer Drugs, vol. 13, no. 1, pp. S7–S9, 2002. View at Scopus
  35. W. J. Köstler, T. Brodowicz, Y. Attems et al., “Docetaxel as rescue medication in anthracycline- and ifostamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial,” Annals of Oncology, vol. 12, no. 9, pp. 1281–1288, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. Q. G. van Hoesel, J. Verweij, G. Catimel et al., “Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group,” Annals of Oncology, vol. 5, no. 6, pp. 539–542, 1994. View at Scopus
  37. A. Santoro, A. Romanini, A. Rosso et al., “Lack of activity of docetaxel in soft tissue sarcomas: results of a phase II study of the Italian Group on Rare Tumors,” Sarcoma, vol. 3, no. 3-4, pp. 177–181, 1999. View at Scopus
  38. A. Minchom, R. L. Jones, C. Fisher et al., “Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma,” Sarcoma, vol. 2010, Article ID 264360, 8 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Verweij, S. M. Lee, W. Ruka et al., “Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group,” Journal of Clinical Oncology, vol. 18, no. 10, pp. 2081–2086, 2000. View at Scopus
  40. R. G. Maki, J. K. Wathen, S. R. Patel et al., “Randomised phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002,” Journal of Clinical Oncology, vol. 25, no. 19, pp. 2755–2763, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Amodio, S. Carpano, C. Manfredi, et al., “Gemcitabine in advanced stage soft tissue sarcoma: a phase II study,” Clinical Therapeutics, vol. 150, no. 1, pp. 17–20, 1999.
  42. O. Merimsky, I. Meller, G. Flusser et al., “Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study,” Cancer Chemotherapy and Pharmacology, vol. 45, no. 2, pp. 177–181, 2000. View at Scopus
  43. E. Späth-Schwalbe, I. Genvresse, A. Koschuth, A. Dietzmann, R. Grunewald, and K. Possinger, “Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas,” Anti-Cancer Drugs, vol. 11, no. 5, pp. 325–329, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. V. Ferraresi, M. Ciccarese, M. C. Cercato et al., “Gemcitabine at fixed dose-rate in patients with advanced soft tissue sarcomas: a mono-institutional phase II study,” Cancer Chemotherapy and Pharmacology, vol. 63, no. 1, pp. 149–155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. J. T. Hartmann, K. Oechsle, J. Huober et al., “An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma,” Investigational New Drugs, vol. 24, no. 3, pp. 249–253, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Okuno, J. Edmonson, M. Mahoney, J. C. Buckner, S. Frytak, and E. Galanis, “Phase II trial of gemcitabine in advanced sarcomas,” Cancer, vol. 94, no. 12, pp. 3225–3229, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. S. R. Patel, V. Gandhi, J. Jenkins et al., “Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation,” Journal of Clinical Oncology, vol. 19, no. 15, pp. 3483–3489, 2001. View at Scopus
  48. J. M. Buesa, R. Losa, A. Fernández et al., “Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation,” Cancer, vol. 101, no. 10, pp. 2261–2269, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. R. Losa, J. Fra, A. López-Pousa et al., “Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas,” Cancer Chemotherapy and Pharmacology, vol. 59, no. 2, pp. 251–259, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. X. García-del-Muro, A. López-Pousa, J. Maurel et al., “Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas Study,” Journal of Clinical Oncology, vol. 29, no. 18, pp. 2528–2533, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. K. M. Leu, L. J. Ostruszka, D. Shewach et al., “Laboratory and clinical evidence of synergistic cytotoxicity of sequential treament with gemcitabine followed by docetaxel in the treatment of sarcoma,” Journal of Clinical Oncology, vol. 22, no. 9, pp. 1706–1712, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. M. L. Hensley, R. Maki, E. Venkatraman et al., “Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial,” Journal of Clinical Oncology, vol. 20, no. 12, pp. 2824–2831, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Ebeling, L. Eisele, P. Schuett et al., “Docetaxel and gemcitabine in the treatment of soft tissue sarcoma—a single-center experience,” Onkologie, vol. 31, no. 1-2, pp. 11–16, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. J.-O. Bay, I. Ray-Coquard, J. Fayette et al., “Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis,” International Journal of Cancer, vol. 119, no. 3, pp. 706–711, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. J. A. Morgan, S. George, J. Desai, et al., “Phase II study of gemcitabine/vinorelbine (GV) as first or second line chemotherapy in patients with metastatic soft tissue sarcoma.,” Journal of Clinical Oncology, vol. 22, no. 14S, pp. 9004–9009, 2004, ASCO Annual Meeting Proceedings.
  56. P. Dileo, J. A. Morgan, D. Zahrieh et al., “Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial,” Cancer, vol. 109, no. 9, pp. 1863–1869, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. A. T. van Oosterom, H. T. Mouridsen, O. S. Nielsen et al., “Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients,” European Journal of Cancer, vol. 38, no. 18, pp. 2397–2406, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. O. S. Nielsen, I. Judson, Q. van Hoesel et al., “Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group,” European Journal of Cancer, vol. 36, no. 1, pp. 61–67, 2000. View at Scopus
  59. R. Coriat, O. Mir, S. Camps et al., “Ambulatory administration of 5-day infusion ifosfamide + mesna: a pilot study in sarcoma patients,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 3, pp. 491–495, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Tursz, “High-dose ifosfamide in the treatment of advanced soft tissue sarcomas,” Seminars in Oncology, vol. 23, supplement 7, no. 3, pp. 34–39, 1996. View at Scopus
  61. A. Le Cesne, G. Demetri, and L. Jean, “Impact of Yondelis in the natural history of patients with pretreated advanced soft tissue sarcomas: long-term follow-up results,” in Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, pp. 17–23, November 2003.
  62. E. G. C. Brain, “Safety and efficacy of ET-743: the French experience,” Anti-Cancer Drugs, vol. 13, no. 1, pp. S11–S14, 2002. View at Scopus
  63. G. Huygh, P. M. J. Clement, H. Dumez et al., “Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients,” Sarcoma, vol. 2006, Article ID 56282, 11 pages, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. S. Delaloge, A. Yovine, A. Taamma et al., “Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients - Preliminary evidence of activity,” Journal of Clinical Oncology, vol. 19, no. 5, pp. 1248–1255, 2001. View at Scopus
  65. A. Yovine, M. Riofrio, J. Y. Blay et al., “Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients,” Journal of Clinical Oncology, vol. 22, no. 5, pp. 890–899, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. J. Blay, N. Penel, A. Italiano, et al., “Trabectedin for advanced sarcomas failing doxorubicin: analysis of 189 unreported patients in a compassionate use program,” Sarcoma, 2009, ASCO Annual Meeting Poster Presentation.
  67. J. Fayette, H. Boyle, S. Chabaud et al., “Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution,” Anti-Cancer Drugs, vol. 21, no. 1, pp. 113–119, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. J. T. Hartmann, K. Oechsle, F. Mayer, L. Kanz, and C. Bokemeyer, “Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas,” Anticancer Research C, vol. 23, no. 2, pp. 1899–1901, 2003. View at Scopus
  69. P. Reichardt, D. Pink, J. Tilgner, A. Kretzschmar, P. C. Thuss-Patience, and B. Dörken, “Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis,” Onkologie, vol. 25, no. 6, pp. 541–546, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. C. Kollmannsberger, W. Brugger, J. T. Hartmann et al., “Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma,” Anti-Cancer Drugs, vol. 10, no. 5, pp. 453–456, 1999. View at Scopus
  71. L. Švancárová, J. Y. Blay, I. R. Judson et al., “Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group,” European Journal of Cancer, vol. 38, no. 4, pp. 556–559, 2002. View at Publisher · View at Google Scholar · View at Scopus
  72. Database, “Consejo General de Colegios Oficiales de Farmaceuticos,” October 2011, https://botplusweb.portalfarma.com/botplus.asp.
  73. “Läkemedelsportalen (Swedish national pharmaceuticals price list),” October 2011, http://www.fass.se/LIF/info/forstabesoket.jsp.
  74. “Nomenclatore Tariffario Regione Lazio, 2010,” 2010, http://www.asl.ri.it/index.php.
  75. J. Branera, J. Puig, M. Gil, R. Bella, A. Darnell, and A. Malet, “Outpatient US-guided percutaneous liver biopsy: technique and complications,” Radiologia, vol. 47, no. 1, pp. 32–36, 2005. View at Scopus
  76. Regionförbundet- regioner prislistor, October 2011, http://www.norrlandstingen.se/lankar_prislistor.htm.
  77. BOC-Numero 64. Precios de los servicios sanitarios, “en los centros hospitalarios, 2007,” October 2011, http://www.fmdv.org.
  78. A. Ringborg, R. Nieuwlaat, P. Lindgren et al., “Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation,” Europace, vol. 10, no. 4, pp. 403–411, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. “Interviews with clinicians”.
  80. “Baxter Healthcare SA”.
  81. “Italian Medicines Agency, 2010,” 2011, http://www.agenziafarmaco.gov.it/en.
  82. M. Vera-Llonch, E. Dukes, J. Rejas, O. Sofrygin, M. Mychaskiw, and G. Oster, “Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective,” European Journal of Health Economics, vol. 11, no. 1, pp. 35–44, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. J. F. Guest, D. Concolino, R. di Vito, C. Feliciani, R. Parini, and A. Zampetti, “Modelling the resource implications of managing adults with Fabry disease in Italy,” European Journal of Clinical Investigation, vol. 41, no. 7, pp. 710–718, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. “World Health Organisation,” 2010, http://www.who.int/en.
  85. G. Mickisch, M. Gore, B. Escudier, G. Procopio, S. Walzer, and M. Nuijten, “Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib,” British Journal of Cancer, vol. 102, no. 1, pp. 80–86, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. M. Ortega-Andreu, H. Pérez-Chrzanowska, R. Figueredo, et al., “Blood loss control with two doses of tranexamic acid in a multimodal protocol for total knee arthroplasty,” The Open Orthopaedics Journal, vol. 5, pp. 44–48, 2011.
  87. A. H. Glenngård and U. Persson, “En blodtransfusion i Sverige - Så mycket kostar den samhället,” Lakartidningen, vol. 103, no. 38, pp. 2752–2756, 2006. View at Scopus
  88. M. Danova, S. Chiroli, G. Rosti, and Q. V. Doan, “Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients,” Tumori, vol. 95, no. 2, pp. 219–226, 2009. View at Scopus
  89. J. I. Mayordomo, A. López, N. Viňolas, et al., “Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain,” Current Medical Research and Opinion, vol. 25, no. 10, pp. 2533–2542, 2009. View at Publisher · View at Google Scholar
  90. F. Kasteng, M. Erlanson, H. Hagberg, E. Kimby, T. Relander, and J. Lundkvist, “Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden,” Acta Oncologica, vol. 47, no. 6, pp. 1029–1036, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Asukai, A. Valladares, C. Camps et al., “Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population,” BMC Cancer, vol. 10, article 26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. M. Percudani, C. Barbui, J. Beecham, and M. Knapp, “Routine outcome monitoring in clinical practice: service and non-service costs of psychiatric patients attending a Community Mental Health Centre in Italy,” European Psychiatry, vol. 19, no. 8, pp. 469–477, 2004. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Mercadante, G. Intravaia, P. Villari et al., “Clinical and financial analysis of an acute palliative care unit in an oncological department,” Palliative Medicine, vol. 22, no. 6, pp. 760–767, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. X. Gómez-Batiste, A. Tuca, E. Corrales et al., “Resource consumption and costs of palliative care services in Spain: a multicenter prospective study,” Journal of Pain and Symptom Management, vol. 31, no. 6, pp. 522–532, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. L. Dahlberg, J. Lundkvist, and H. Lindman, “Health care costs for treatment of disseminated breast cancer,” European Journal of Cancer, vol. 45, no. 11, pp. 1987–1991, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. J. Hjelmgren, J. Ceberg, U. Persson, and T. A. Alvegård, “The cost of treating pancreatic cancer: a cohort study based on patients' records from four hospitals in Sweden,” Acta Oncologica, vol. 42, no. 3, pp. 218–226, 2003. View at Publisher · View at Google Scholar · View at Scopus
  97. I. Judson, J. A. Radford, M. Harris et al., “Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group,” European Journal of Cancer, vol. 37, no. 7, pp. 870–877, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. J. F. Guest, E. Sladkevicius, N. Gough, M. Linch, and R. Grimer, “Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom,” Sarcoma, vol. 2013, Article ID 863056, 9 pages, 2013. View at Publisher · View at Google Scholar
  99. S. Capri, A. Ceci, L. Terranova et al., “Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies,” Drug Information Journal, vol. 35, no. 1, pp. 189–201, 2001. View at Scopus
  100. J. López-Bastida, J. Oliva, F. Antoñanzas, et al., “Spanish recommendations on economic evaluation of health technologies,” The European Journal of Health Economics, vol. 11, no. 5, pp. 513–520, 2010.
  101. F. Borgström, O. Johnell, J. A. Kanis, A. Oden, D. Sykes, and B. Jönsson, “Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study,” PharmacoEconomics, vol. 22, no. 17, pp. 1153–1165, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. A. M. Gray, P. M. Clarke, J. Wolstenholme, et al., Applied Methods of Cost-Effectiveness Analysis in Health Care, Oxford University Press, New York, NY, USA, 2010.
  103. “SSG XX- A Scandinavian Sarcoma Group treatment protocol for adult patients with non-metastatic high-risk soft tissue sarcoma of the extremities and trunk wall,” Scandinavian Sarcoma Group and Oncologic Center, Lund, Sweden, 2007.
  104. W. T. A. van der Graaf, I. Judson, J. Verweij et al., “Results of a randomised phase III trial (EORTC, 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC soft tissue and bone sarcoma group,” ESMO Congress. Abstract LBA7, October 2012, http://oncologypro.esmo.org/meeting-resources/meeting-abstracts/european-society-for-medical-oncology-esmo-2012/results-of-a-randomised-phase-iii-trial-2882.aspx.